Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 16, 2022

Pyrotinib Plus Trastuzumab and Chemotherapy for the Treatment of Patients With HER2-Positive Metastatic Breast Cancer

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
Breast Cancer Res Treat 2022 Oct 30;[EPub Ahead of Print], XF Xie, QY Zhang, JY Huang, LP Chen, XF Lan, X Bai, L Song, SL Xiong, SJ Guo, CW Du

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading